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Ankyrin–Tiam1 Interaction Promotes Rac1 Signaling and Metastatic 
Breast Tumor Cell Invasion and Migration
 
Lilly Y.W. Bourguignon, Hongbo Zhu, Lijun Shao, and Yue Wei Chen
 
Department of Cell Biology and Anatomy, School of Medicine, University of Miami, Miami, Florida 33136
 
Abstract. 
 
Tiam1 (T-lymphoma invasion and metastasis 
1) is one of the known guanine nucleotide (GDP/GTP) 
exchange factors (GEFs) for Rho GTPases (e.g., Rac1) 
and is expressed in breast tumor cells (e.g., SP-1 cell 
line). Immunoprecipitation and immunoblot analyses 
indicate that Tiam1 and the cytoskeletal protein, 
ankyrin, are physically associated as a complex in vivo. 
In particular, the ankyrin repeat domain (ARD) of 
ankyrin is responsible for Tiam1 binding. Biochemical 
studies and deletion mutation analyses indicate that the 
11–amino acid sequence between amino acids 717 and 
727 of Tiam1 (
 
717
 
GEGTDAVKRS
 
727
 
L) is the ankyrin-
binding domain. Most importantly, ankyrin binding to 
Tiam1 activates GDP/GTP exchange on Rho GTPases 
(e.g., Rac1).
Using an 
 
Escherichia coli
 
–derived calmodulin-bind-
ing peptide (CBP)–tagged recombinant Tiam1 (amino 
acids 393–728) fragment that contains the ankyrin-
binding domain, we have detected a specific binding in-
teraction between the Tiam1 (amino acids 393–738) 
fragment and ankyrin in vitro. This Tiam1 fragment also 
acts as a potent competitive inhibitor for Tiam1 binding 
to ankyrin. Transfection of SP-1 cell with Tiam1 cDNAs 
stimulates all of the following: (1) Tiam1–ankyrin asso-
ciation in the membrane projection; (2) Rac1 activa-
tion; and (3) breast tumor cell invasion and migration. 
Cotransfection of SP1 cells with green fluorescent pro-
tein (GFP)–tagged Tiam1 fragment cDNA and Tiam1 
cDNA effectively blocks Tiam1–ankyrin colocalization 
in the cell membrane, and inhibits GDP/GTP exchange 
on Rac1 by ankyrin-associated Tiam1 and tumor-spe-
cific phenotypes. These findings suggest that ankyrin–
Tiam1 interaction plays a pivotal role in regulating 
Rac1 signaling and cytoskeleton function required for 
oncogenic signaling and metastatic breast tumor cell 
progression.
Key words: Tiam1 • ankyrin • Rac1 signaling • inva-
sion/migration • metastatic breast tumor cells
 
Introduction
 
Members of the Rho subclass of the ras superfamily (small
molecular masses GTPases, e.g., Rac1, RhoA, and Cdc42)
are known to be associated with changes in the mem-
brane-linked cytoskeleton (Ridley and Hall, 1992; Hall,
1998). For example, activation of Rac1, RhoA, and Cdc42
has been shown to produce specific structural changes in
the plasma membrane cytoskeleton associated with mem-
brane ruffling, lamellipodia, filopodia, and stress fiber for-
mation (Ridley and Hall, 1992; Hall, 1998). The coordi-
nated activation of these GTPases is thought to be a
possible mechanism underlying cell motility, an obvious
prerequisite for metastasis (Jiang et al., 1994; Dickson and
Lippman, 1995; Lauffenburger and Horwitz, 1996).
Several guanine nucleotide exchange factors (GEFs,
 
1
 
the dbl or DH family) have been identified as oncogenes
because of their ability to upregulate Rho GTPase activity
during malignant transformation (Van Aelst and D’Souza-
Schorey, 1997). One of these GEFs is Tiam1 (T-lymphoma
invasion and metastasis 1), which was identified by retrovi-
ral insertional mutagenesis and selected for its invasive
cell behavior in vitro (Habets et al., 1994, 1995). This mol-
ecule is largely hydrophilic and contains several functional
domains found in signal transduction proteins. For exam-
ple, the COOH-terminal region of the Tiam1 molecule has
a Dbl homology (DH) domain (Hart et al., 1991, 1994; Ha-
bets et al., 1994) and an adjacent pleckstrin homology
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Abbreviations used in this paper:
 
 ARD, ankyrin repeat domain; CBP,
calmodulin-binding peptide; DH, Dbl homology; GFP, green fluorescent
protein; GFP-SBD, GFP-tagged spectrin binding domain; GEF, guanine nu-
cleotide exchange factor; HA, hemagglutinin; PH, pleckstrin homology; PHn,
NH
 
2
 
-terminal PH; Rh, rhodamine; S1P, sphingosine-1-phosphate; SBD, spec-
trin binding domain; Tiam1, T lymphoma invasion and metastasis 1.
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(PH) domain, which exists in most GEFs (Hart et al., 1991,
1994; Habets et al., 1994; Lemmon et al., 1996). In particu-
lar, the DH domain of these proteins exhibits GDP/GTP
exchange activity for specific members of the Ras super-
family of GTP-binding proteins (Hart et al., 1991, 1994).
Tiam1 also contains an additional PH domain, a Discs-
large homology region (DHR; Habets et al., 1994; Pon-
tings and Phillips, 1995), and a potential myristoylation
site in the NH
 
2
 
-terminal part of the protein (Habets et al.,
1994).
Overexpression of both NH
 
2
 
 and COOH terminally
truncated as well as full-length Tiam1 proteins induces the
invasive phenotype in otherwise noninvasive lymphoma
cell lines (Michiels et al., 1995). It is also well established
that Tiam1 is capable of activating Rac1 in vitro as a GEF,
and induces membrane cytoskeleton–mediated cell shape
changes, cell adhesion, and cell motility (Woods and Bry-
ant 1991; Michiels et al., 1995; Nobes and Hall, 1995; Van
Leeuwen et al., 1995). These findings have prompted in-
vestigations into the mechanisms involved in the regula-
tion of Tiam1. In fact, it has been found that addition
of certain serum-derived lipids (e.g., sphingosine-1-phos-
phate [S1P] and LPA) to T-lymphoma cells promotes
Tiam1-mediated Rac1 signaling and T-lymphoma cell in-
vasion (Stam et al., 1998). A Tiam1 transcript has been de-
tected in breast cancer cells (Habets et al., 1995). Tiam1 is
shown to function as a GEF in activating Rac1 signaling in
breast tumor cells (Bourguignon et al., 2000). The ques-
tion of how this molecule is regulated in invasive and met-
astatic processes of breast cancer cells is addressed in the
present study.
Ankyrin belongs to a family of cytoskeletal proteins that
mediate linkage of integral membrane proteins with the
spectrin-based skeleton in regulating a variety of biologi-
cal activities (Bennett, 1992; Bennett and Gilligan, 1993;
De Matteis and Morrow, 1998). Presently, at least three
ankyrin genes have been identified: 
 
ankyrin
 
 
 
1
 
 (ANK1 or
 
ankyrin R
 
), 
 
ankyrin 2
 
 (ANK2 or ankyrin B), and 
 
ankyrin 3
 
(ANK3 or 
 
ankyrin G
 
) (Lambert et al., 1990; Lux et al.,
1990; Tse et al., 1991; Otto et al., 1991; Peters and Lux
1993; Kordeli et al., 1995; Peters et al., 1995). All ankyrin
species (e.g., ANK1, ANK2, and ANK3) are monomers
comprised of two highly conserved domains and a variable
domain. Both conserved domains are located in the NH
 
2
 
-
terminal region and include a membrane-binding site
(
 
z
 
89–95 kD, also called the ankyrin repeat domain
[ARD]; Davis and Bennet, 1990; Lux et al., 1990), and a
spectrin binding domain (SBD, 
 
z
 
62 kD; Platt et al., 1993).
The striking feature shared by all three forms of ankyrins
is the repeated 33–amino acid motif present in 24 contigu-
ous copies within the ARD. The ARD of ANK1, ANK2,
and ANK3 is highly conserved. A number of tumor cells
express ankyrin such as ANK1 and ANK3 (Bourguignon
et al., 1998a,b; Zhu and Bourguignon, 2000). Most re-
cently, we have found that ankyrin’s ARD interacts with
the adhesion molecule, CD44, and promotes tumor cell
migration (Zhu and Bourguignon, 2000). In addition, the
ARD domain (also referred to as cdc 10 repeats, cdc10/
SW16 repeats, and SW16/ANK repeats) has been detected
in a number of functionally distinct proteins participating
in protein–protein binding and protein–DNA interactions
(Davis and Bennett, 1990; Lux et al., 1990).
In this study, we have focused on the regulatory aspect
of Tiam1-Rac1 signaling in metastatic breast tumor cells
(SP-1 cell line). Our results indicate that Tiam1 interacts
with ankyrin in vivo and in vitro. In particular, the ankyrin
repeat domain (ARD) is directly involved in Tiam1 bind-
ing. Biochemical analyses show that the Tiam1 fragment
(amino acids 393–738) contains an ankyrin-binding site
and competes for Tiam1 binding to ankyrin. Most impor-
tantly, the binding of ankyrin, in particular, the ankyrin re-
peat domain (ARD), to Tiam1 activates Rho-like GTP-
ases such as Rac1. Overexpression of Tiam1 in SP-1 cells
by transfecting Tiam1 cDNA induces Tiam1–ankyrin asso-
ciation in the cell membrane, Rac1 signaling, and meta-
static phenotypes. Both Tiam1–ankyrin interaction and
tumor-specific behaviors are significantly inhibited by
cotransfecting SP-1 cells with the Tiam1 (amino acids 393–
738) fragment cDNA and Tiam1 cDNA. Our observations
suggest that Tiam1 interaction with ankyrin promotes Rho
GTPase activation and cytoskeletal changes required for
metastatic breast tumor cell invasion and migration.
 
Materials and Methods
 
Cell Culture
 
Mouse breast tumor cells (e.g., SP1 cell line; provided by Dr. Bruce El-
liott, Department of Pathology and Biochemistry, Queen’s University,
Kingston, Ontario, Canada) were used in this study. Specifically, the SP1
cell line was derived from a spontaneous intraductal mammary adenocar-
cinoma that arose in a retired female CBA/J breeder in the Queen’s Uni-
versity animal colony. These cells were capable of inducing lung me-
tastases by sequential passage of SP1 cells into mammary gland (Elliott
et al., 1988). These cells were cultured in RPMI 1640 medium supple-
mented with either 5 or 20% FCS, folic acid (290 mg/l), and sodium pyru-
vate (100 mg/l). COS-7 cells were obtained from American Type Culture
Collection and grown routinely in DME containing 10% FBS, 1%
glutamine, 1% penicillin, and 1% streptomycin.
 
Antibodies and Reagents
 
For the preparation of polyclonal rabbit anti-Tiam1 antibody, specific syn-
thetic peptides (
 
z
 
15–17 amino acids unique for the COOH-terminal se-
quence of Tiam1) were prepared by the Peptide Laboratories of the De-
partment of Biochemistry and Molecular Biology using an automatic
synthesizer (model ACT350; Advanced Chemtech). These Tiam1-related
polypeptides were conjugated to polylysine and subsequently injected into
rabbits to raise the antibodies. The anti-Tiam1–specific antibody was
collected from each bleed and stored at 4
 
8
 
C containing 0.1% azide. The
anti-Tiam1 IgG fraction was prepared by conventional DEAE-cellulose
chromatography. Mouse monoclonal anti-hemagglutinin (HA epitope)
antibody (clone 12 CA5) and mouse monoclonal anti–green fluorescent
protein (GFP) antibody were purchased from Boehringer Mannheim and
PharMingen, respectively.
 
 Escherichia coli
 
 (
 
E. coli
 
)–derived GST-tagged
Rac1/Cdc42 and GST-tagged RhoA was provided by Dr. Richard A. Ceri-
one (Cornell University, Ithaca, NY) and Dr. Martin Schwartz (Scripps
Research Institute, La Jolla, CA), respectively. Mouse monoclonal eryth-
rocyte ankyrin (ANK1) and ANK3 antibodies were prepared as described
previously (Bourguignon et al., 1993a). Rabbit anti-ANK3 antibody was
provided by Dr. L.L. Peters (Jackson Laboratory, Bar Harbor, ME; Peters
et al., 1995).
 
Cloning, Expression, and Purification of GST-tagged 
Ankyrin Repeat Domain (GST-ARD) and GFP-tagged 
Spectrin Binding Domain (GFP-SBD) of Ankyrin
 
pGEX-2TK recombinant plasmid expressing GST-ARD (NH
 
2
 
-terminal
portion of ankyrin, residues 1–834) was constructed as follows. Two
pGEX-2TK recombinant plasmids pA3-79 (expressing epithelial Ank3
NH
 
2
 
-terminal 1–455 amino acids) and pA3-88 (expressing epithelial Ank3
 Bourguignon et al. 
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NH
 
2
 
-terminal 317–834 amino acids; Peters et al., 1995) were provided by
Dr. L.L. Peters from the Jackson Laboratory. The two plasmids were di-
gested by EcoRI (one of pGEX-2TK vector cloning sites) and NheI (in
ankyrin cDNA 1,176 bp) sequentially. The digested products were run in
1% agarose gel and purified with a purification kit (QIAGEN). The larger
cDNA fragment in pA3-79–digested products (containing the pGEX-2TK
vector and ankyrin cDNA 1–1,176 bp) and the smaller one in pA3-88–
digested products (containing ankyrin cDNA 1,176–2,556 bp) were cut
and purified. These two cDNA fragments were ligated and transformed to
INV
 
a
 
F
 
9
 
-competent cells. The obtained clones were sequenced to verify
the correct generation of the full-length ARD.
Spectrin binding domain (SBD) cDNA of human erythrocyte ankyrin
was cloned into the eukaryotic expression vector, GFPN1 (CLONTECH
Laboratories, Inc.) using the PCR-based cloning strategy. Ankyrin’s SBD
cDNA was amplified by PCR with two specific primers (left, 5
 
9
 
-CGCTC-
GAGATGAAGGCTGAGAGGCGGGATTCC-3
 
9
 
 and right, 5
 
9
 
-ATAA-
GCTTCAGGGGCGTCGGGGTCCTTCT-3
 
9
 
) linked with specific en-
zyme digestion site (XhoI and HindIII). The PCR product, which was
digested with XhoI and HindIII, was purified with QIAquick PCR purifi-
cation kit (QIAGEN). Ankyrin’s SBD cDNA fragment was cloned into
GFPN1 vector digested with XhoI and HindIII. The cDNA sequence was
confirmed by nucleotide sequencing analysis. The GFP-tagged spectrin
binding domain (GFP-SBD) of ankyrin is expressed as an 89-kD polypep-
tide in SP1 or COS-7 cells by SDS-PAGE and immunoblot analyses. The
89-kD GFP-SBD (but not ARD) displays specific spectrin binding prop-
erty as described previously (Platt et al., 1993). Subsequently, GFP-SBD
was isolated from anti-GFP–conjugated affinity columns and used in vari-
ous in vitro binding experiments as described below.
 
Expression Constructs
 
Both the full-length mouse Tiam1 cDNA (FL1591) and the NH
 
2
 
 termi-
nally truncated Tiam1 cDNA (C1199) were provided by Dr. John G. Col-
lard (The Netherlands Cancer Institute, The Netherlands). Specifically,
the full-length Tiam1 (FL1591) cDNA was cloned into the eukaryotic ex-
pression vector, pMT2SM. The truncated C1199 Tiam1 cDNA (carrying a
hemagglutinin epitope [HA] tag at the 3
 
9
 
 end) was cloned in the eukary-
otic expression vector, pUTSV1 (Eurogentec, Belgium).
The deletion construct, HA-tagged C1199 Tiam1
 
D
 
717-727 (deleting the
sequence between amino acids 717 and 727 of Tiam1) was derived from
C1199 Tiam1 using QuickChange
 
TM
 
 site-directed mutagenesis kit (Strat-
agene). In brief, two complimentary mutagenic oligonucleotide primers
containing the desired deletion (5
 
9
 
-CCCAACCATCAACCAGGTGTT-
TGAGGGAATATTTGATG-3
 
9
 
) was designed and synthesized. First,
the cycling reaction, using 30-ng double-stranded DNA template of C1199
Tiam1 plasmid and two complimentary primers, was performed to pro-
duce mutated cDNA according to the manufacturer’s instruction. Subse-
quently, 1 
 
m
 
l of the DpnI restriction enzyme (10 U/
 
m
 
l) was added directly
to the cycling reaction products to digest the parental supercoiled double-
stranded DNA. This DpnI-treated cDNA was used to transform super-
competent cells (e.g., 
 
Epicurian coli
 
 XL 1-blue). Finally, the deletion con-
struct was confirmed by DNA sequencing.
The Tiam1 (amino acids 393–728) fragment was cloned into calmodu-
lin-binding peptide (CBP)–tagged vector (pCAL-n; Stratagene) using the
PCR-based cloning strategy. Using human Tiam1 cDNA as a template,
the Tiam1 fragment was amplified by PCR with two specific primers (left,
5
 
9
 
-AACTCGAGATGAGTACCACCAACAGTGAG-3
 
9
 
 and right, 5
 
9
 
-
AAAAAGCTTTCAGCCATCTGGAACAGTGTCATC-3
 
9
 
) linked with
a specific enzyme digestion site (XhoI or HindIII). The PCR product,
which was digested with XhoI and HindIII, was purified with QIAquick
PCR purification kit (QIAGEN). The Tiam1 fragment cDNA was cloned
into pCAL-n vector digested with XhoI and HindIII. The inserted Tiam1
fragment sequence was confirmed by nucleotide sequencing analyses. The
recombinant plasmids were transformed to BL21-DE3 to produce CBP-
tagged Tiam1 fragment fusion protein. This fusion protein was purified
from bacteria lysate by calmodulin affinity resin column (Sigma Chemi-
cal Co.).
The Tiam1 fragment cDNA was also cloned into pEGFPN1 vector
(CLONTECH Laboratories, Inc.) digested with XhoI and HindIII to cre-
ate GFP-tagged Tiam1 fragment cDNA. The inserted Tiam1 fragment se-
quence was confirmed by nucleotide sequencing analyses. This GFP-
tagged Tiam1 fragment cDNA was used for transient expression in SP1
cells as described below. The GFP-tagged Tiam1 fragment is expressed as
a 68-kD polypeptide in SP1 or COS-7 cells by SDS-PAGE and immuno-
blot analyses.
 
Cell Transfection
 
To establish a transient expression system, cells (e.g., SP-1 or COS-7 cells)
were transfected with various plasmid DNAs including Tiam1 cDNAs
(e.g., the full-length mouse Tiam 1 cDNA [FL1591], or HA-tagged C1199
Tiam1 cDNA, or HA-tagged C1199 Tiam1
 
D
 
717-727 cDNA, or GFP-
tagged Tiam1 fragment cDNA, or HA-tagged C1199 Tiam1 cDNA plus
GFP-tagged Tiam1 fragment cDNA (cotransfection), or vector control
constructs) using electroporation methods. In brief, cells (e.g., SP-1 or
COS-7 cells) were plated at a density of 10
 
6
 
 cells per 100-mm dish, and
were transfected with 25 
 
m
 
g/dish plasmid DNA using electroporation at
230 V and 960 
 
m
 
FD with a gene pulser (Bio-Rad). Transfected cells were
grown in 5 or 20% FCS-containing culture medium for at least 24–48 h.
Various transfectants were analyzed for the expression of Tiam1 or HA-
tagged (or GFP-tagged) Tiam1 mutant proteins by immunoblot, immuno-
precipitation, and functional assays as described below.
 
Immunoprecipitation and Immunoblotting Techniques
 
SP-1 cells or COS cells (e.g., untransfected or transfected by various
Tiam1 cDNAs including the full-length mouse Tiam1 cDNA [FL1591] or
HA-tagged C1199 Tiam1 cDNA) were first extracted with a solution con-
taining 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 1% NP-40 buffer, fol-
lowed by solubilizing in SDS sample buffer, and analyzed by SDS-PAGE
(with 7.5% gel). Separated polypeptides were transferred onto nitrocellu-
lose filters. After blocking nonspecific sites with 3% BSA, the nitrocellu-
lose filters were incubated with 5 
 
m
 
g/ml either of rabbit anti-Tiam1 or
mouse anti-HA (or preimmune serum) plus peroxidase-conjugated goat
anti–rabbit IgG or goat anti–mouse IgG (1:10,000 dilution), respectively.
In controls, peroxidase-conjugated normal mouse IgG or preimmune rab-
bit IgG was also incubated with anti-Tiam1–mediated immunocomplex.
The blots were developed using ECL chemiluminescence reagent (Amer-
sham Life Science) according to the manufacturer’s instructions.
In some cases, SP-1 cells (transfected with HA-tagged C1199 Tiam1
cDNA, or HA-tagged C1199 Tiam1
 
D
 
717-727 cDNA, or GFP-tagged
Tiam1 fragment cDNA, or cotransfected with HA-tagged C1199 Tiam1
cDNA and GFP-tagged Tiam1 fragment cDNA) were immunoblotted
with anti-HA antibody (5 
 
m
 
g/ml) or anti-GFP antibody (5 
 
m
 
g/ml), respec-
tively, followed by incubation with HRP-conjugated goat anti–mouse IgG
(1:10,000 dilution) at room temperature for 1 h.
SP-1 cells were also immunoprecipitated with rabbit anti-Tiam1 (5 
 
m
 
g/ml)
or mouse antiankyrin antibodies (e.g., 5 
 
m
 
g/ml of either mouse anti-ANK3
antibody or mouse anti-ANK1 antibody), followed by immunoblotting/re-
blotting with ankyrin antibodies (e.g., 1 
 
m
 
g/ml mouse anti-ANK3 anti-
body, or 5 
 
m
 
g/ml mouse anti-ANK1 antibody, or 1 
 
m
 
g/ml rabbit anti-
Tiam1), respectively, followed by incubation with HRP-conjugated goat
anti–mouse IgG or goat anti–rabbit IgG (1:10,000 dilution) at room tem-
perature for 1 h. In reblotting controls, both peroxidase-conjugated nor-
mal mouse IgG or rabbit preimmune IgG was also used. The blots were
developed using ECL chemiluminescence reagent (Amersham Life Sci-
ence) according to the manufacturer’s instructions.
 
Effects of Synthetic Peptides on
Ankyrin-Tiam1 Interaction
 
Nitrocellulose discs (1-cm diam) were coated with 
 
z
 
1 
 
m
 
g of a panel
of synthetic peptides including the ankyrin-binding region peptide
(
 
717
 
GEGTDAVKRS
 
727
 
L), a scrambled peptide (GRATLEGSDKV) and
another Tiam1-related peptide (
 
399
 
GTIKRAPFLG
 
409
 
P; synthesized by Dr.
Eric Smith, University of Miami). After coating, the unoccupied sites on
the discs were blocked by incubation with a solution containing 20 mM
Tris-HCl, pH 7.4, and 0.3% BSA at 4
 
8
 
C for 2 h. The discs were incubated
with various concentration of 
 
125
 
I-labeled cytoskeletal proteins (erythro-
cyte ankyrin/ARD/ankyrin’s SBD/spectrin; 
 
z
 
3000 cpm/ng) at 4
 
8
 
C for 2 h
in 1 ml binding buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2%
BSA).
In some experiments, 
 
125
 
I-labeled Tiam1 (
 
z
 
3,000 cpm/ng) was incu-
bated with ankyrin-coated beads in the presence of various concentrations
(10
 
2
 
10
 
–10
 
2
 
6 
 
M) of unlabeled synthetic peptide (e.g., 
 
717
 
GEGTDAV-
KRS
 
727
 
L or the scrambled sequence, GRATLEGSDKV, or another
Tiam1-related peptide, 
 
399
 
GTIKRAPFLG
 
409
 
P) at 4
 
8
 
C for 2 h in 1 ml bind-
ing buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% BSA). 
 
125
 
I-
labeled Tiam1 fragment (
 
z
 
3,000 cpm/ng) was also incubated with beads
containing 1.0 
 
m
 
g of each of the following four proteins: intact ankyrin,
ARD, or spectrin binding domain of ankyrin (GFP-SBD), or GFP alone.
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After binding, the peptide-coated discs (or cytoskeletal protein–conju-
gated beads) were washed three times in the binding buffer, and the ra-
dioactivity associated with the peptide-coated discs (or cytoskeletal pro-
tein–conjugated beads) was estimated. As a control, the ligands were
also incubated with uncoated nitrocellulose discs (or beads) to determine
the binding observed because of the stickiness of various ligands. Non-
specific binding was observed in these controls. In the peptide competi-
tion assay, the specific binding observed in the absence of any of the
competing peptides is designated as 100%. The results represent an aver-
age of duplicate determinations for each concentration of the competing
peptide used.
 
Binding of Ankyrin or ARD to Tiam1 In Vitro
 
Aliquots (0.5–1.0 
 
m
 
g of protein) of purified Tiam1 (e.g., intact Tiam1, or
C1199 Tiam1, or Tiam1 fragment)–conjugated beads were incubated in
0.5 ml of binding buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1%
BSA, and 0.05% Triton X-100) containing various concentrations (10–800
ng/ml) of 
 
125
 
I-labeled intact ankyrin (purified from human erythrocytes;
5,000 cpm/ng protein) or 
 
125
 
I-labeled recombinant ARD fragment at 4
 
8
 
C
for 4 h. Specifically, equilibrium binding conditions were determined by
performing a time course (1–10 h) of 
 
125
 
I-labeled ankyrin (or ARD) bind-
ing to Tiam1 at 4
 
8
 
C. The binding equilibrium was found to be established
when the in vitro ankyrin (or ARD)-Tiam1 binding assay was conducted
at 4
 
8
 
C after 4 h. After binding, beads were washed extensively in binding
buffer, and the bead-bound radioactivity was counted.
As a control, 
 
125
 
I-labeled ankyrin or 
 
125
 
I-labeled ARD was also incu-
bated with uncoated beads to determine the binding observed because of
the nonspecific binding of various ligands. Nonspecific binding, which
represented 
 
z
 
20% of the total binding, was always subtracted from the
total binding. Our binding data are highly reproducible. The values ex-
pressed in the Results represent an average of triplicate determinations
of three to five experiments with an SD less than 
 
6 
 
5%. In some cases,
 
125
 
I-ankyrin (1–10 ng) was incubated with a polyacrylamide gel contain-
ing purified Tiam1 (obtained from anti-Tiam1 affinity column chroma-
tography) in the absence or the presence of 100-fold excess amount of
unlabeled ankyrin/spectrin (in the same binding buffer as described
above) for 1 h at room temperature. After incubation, the gel was washed
five times with the same binding solution and analyzed by autoradio-
graphic analyses.
An in vitro binding assay designed to measure the stoichiometry of
GST-ARD fusion protein and C1199 Tiam1 was also carried out. Specifi-
cally, in each reaction, 15–60 
 
m
 
l of glutathione-Sepharose bead slurry con-
taining GST-ARD or GST alone was suspended in 0.5 ml of binding
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% BSA, and 0.05%
Triton X-100). Purified C1199 Tiam1 (0.5–1.0
 
 m
 
g) was added to the bead
suspension in the absence or the presence of an excess amount of CBP-
tagged Tiam1 fragment (100
 
 m
 
g) at 4
 
8
 
C for 4 h. After binding, the GST fu-
sion protein was eluted with its associated C1199 Tiam1 using 150
 
 m
 
l of
50 mM Tris-HCl, pH 8.0, buffer containing 30 mM glutathione. The
amount of eluted GST fusion protein and C1199 Tiam1 was determined
by SDS-PAGE and Coomassie blue staining followed by densitometric
scanning using a software NIH Image V1.54. The amount of ARD (mol)
per C1199 Tiam1 (mol) was calculated. Values represent relative binding
abilities averaged from three experiments 
 
6 
 
SEM.
 
Binding of 
 
125
 
I-Labeled Ankyrin to C1199 Tiam1 and 
the Mutant Protein
 
SP1 cells were transfected with HA-tagged C1199 Tiam1 cDNA, or HA-
tagged C1199 Tiam1
 
D
 
717-727 cDNA, or vector alone. These transfectants
were extracted with a solution containing 50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, and 1% NP-40, and immunoprecipitated with anti-HA immunoaf-
finity beads. Subsequently, aliquots (50 ng proteins) of these beads were
incubated with 0.5 ml of a binding buffer (20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 0.1% BSA, and 0.05% Triton X-100) in presence of various concen-
trations (10–400 ng/ml) of 
 
125
 
I-labeled ankyrin (5,000 cpm/ng protein) at
4
 
8
 
C for 5 h. After binding, beads were washed extensively in binding
buffer and the bead-bound radioactivity was counted.
As a control, 
 
125
 
I-labeled ankyrin was also incubated with uncoated
beads to determine the binding observed because of the nonspecific bind-
ing of the ligand. Nonspecific binding, which represented 
 
z
 
15–20% of the
total binding, was always subtracted from the total binding. The values ex-
pressed in the Results represent an average of triplicate determinations of
three to five experiments with an SD less than 
 
6 
 
5%.
 
Tiam1-mediated GDP/GTP Exchange for Rho GTPases
 
Purified 
 
E. coli
 
–derived GST-tagged GTPases (e.g., Rac1, Cdc42, or
RhoA; 20 pmol) were preloaded with GDP (30 
 
m
 
M) in 10 
 
m
 
l buffer con-
taining 25 mM Tris-HCl, pH 8.0, 1 mM DTT, 4.7 mM EDTA, 0.16 mM
MgCl
 
2
 
, and 200 
 
m
 
g/ml BSA at 37
 
8
 
C
 
 
 
for 7 min. To terminate preloading
procedures, additional MgCl
 
2 
 
was added to the solution (reaching a final
concentration of 9.16 mM) as described previously (Zhang et al., 1995).
Tiam1 was isolated from COS-7 cells (transfected with either the full-
length Tiam1 cDNA or HA-tagged C1199 Tiam1 cDNA) or SP1 cells
(transfected with various plasmid DNAs such as HA-tagged C1199 Tiam1
cDNA, GFP-tagged Tiam1 fragment cDNA, or HA-tagged C1199 Tiam1
cDNA plus GFP-tagged Tiam1 fragment cDNA [as cotransfection] or
vector alone) using anti-Tiam1 (or anti-HA or anti-GFP)–conjugated
beads. In some cases, ankyrin-associated Tiam1 was isolated from SP1
cells (transfected with HA-tagged C1199 Tiam1 cDNA, GFP-tagged
Tiam1 fragment cDNA, or HA-tagged C1199 Tiam1 cDNA plus GFP-
tagged Tiam1 fragment cDNA [as a cotransfection], or vector alone) using
antiankyrin-conjugated beads.
Subsequently, 2 pmol of Tiam1, isolated from untransfected or trans-
fected cells according to the procedures described above, was preincu-
bated with no ankyrin or ankyrin (e.g., 1 
 
m
 
g/ml of either intact ankyrin or
ARD), followed by adding to the reaction buffer containing 20 mM Tris-
HCl, pH 8.0, 100 mM NaCl, 10 mM MgCl
 
2
 
, 100 
 
m
 
M AMP-PNP, 0.5 mg/ml
BSA, and 2.5 
 
m
 
M GTP-
 
g
 
–
 
35
 
S (
 
z
 
1,250 Ci/mmol). Subsequently, 2.5 pmol
GDP-loaded GST-tagged Rho GTPases (e.g., Rac1, RhoA, or Cdc42) or
GDP-treated GST were mixed with the reaction buffer containing Tiam1
and GTP-
 
g
 
–
 
35
 
S to initiate the exchange reaction at room temperature. At
various time points, the reaction of each sample was terminated by adding
ice-cold termination buffer containing 20 mM Tris-HCl, pH 8.0, 100 mM
NaCl, and 10 mM MgCl
 
2
 
 as described previously (Michiels et al., 1995;
Zhang et al., 1995). The termination reactions were filtered immediately
through nitrocellulose filters, followed by one wash with the termination
buffer. The filters were dissolved completely in scintillation fluid, and the
radioactivity associated with the filters were measured by scintillation
fluid. The amount of GTP-
 
g
 
–
 
35
 
S bound to Tiam1 or control sample (pre-
immune serum–conjugated Sepharose beads) in the absence of Rho GTP-
ases (e.g., Rac1, Cdc42, or RhoA) was subtracted from the original values.
Data represent an average of triplicates from three to five experiments.
SD 
 
, 
 
5%.
 
Double Immunofluorescence Staining
 
SP1 cells (untransfected or transfected with various plasmid DNAs such
as HA-tagged C1199 Tiam1 cDNA, GFP-tagged Tiam1 fragment cDNA,
or HA-tagged C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment
cDNA [as a cotransfection], or vector alone) were first washed with PBS
(0.1 M phosphate buffer, pH 7.5, and 150 mM NaCl) buffer and fixed by
2% paraformaldehyde. Subsequently, cells were rendered permeable by
ethanol treatment followed by staining with different immunoreagents.
Specifically, untransfected cells were incubated with rhodamine (Rh)-con-
jugated mouse anti-ANK3 (50 
 
m
 
g/ml) and fluorescein (FITC)-conjugated
rabbit anti-Tiam1 (50 
 
m
 
g/ml), respectively. HA-tagged C1199 cDNA–
transfected cells were stained with Rh-conjugated mouse anti-ANK3 anti-
body (50 
 
m
 
g/ml) and FITC-conjugated mouse anti-HA IgG (50 
 
m
 
g/ml), re-
spectively. GFP-tagged Tiam1 fragment cDNA–transfected cells were
labeled with Rh-conjugated anti-ANK3 (50 
 
m
 
g/ml). Some SP1 transfec-
tants (cotransfected with Tiam1 fragment cDNA and HA-tagged C1199
Tiam1 cDNA) were stained with Rh-conjugated anti-HA (50 
 
m
 
g/ml) or
Rh-conjugated anti-ANK3 (50 
 
m
 
g/ml), respectively. To detect nonspecific
antibody binding, vector-transfected cells were labeled with Rh-conju-
gated anti-ANK3 (50 
 
m
 
g/ml) followed by incubating with FITC-conju-
gated anti-HA (50 mg/ml). No anti-HA labeling was observed in such
control samples. In some experiments, GFP-tagged Tiam1 fragment
cDNA–transfected cells were also incubated with Rh-labeled rabbit pre-
immune IgG (50 mg/ml). No nonspecific rhodamine staining was detected
in these samples. The FITC- and Rh-labeled samples were examined with
a confocal laser scanning microscope (MultiProbe 2001 inverted CLSM
system; Molecular Dynamics).
Tumor Cell Migration and Invasion Assays
24 transwell units were used for monitoring in vitro cell migration and in-
vasion as described previously (Merzak et al., 1994; Bourguignon et al.,
1998b, 2000). Specifically, the 5-mm porosity polycarbonate filters coated
with the reconstituted basement membrane substance Matrigel (Collabo-
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rative Research) were used for the cell invasion assay (Merzak et al., 1994;
Bourguignon et al., 1998b). The 5-mm porosity polycarbonate filters (with-
out Matrigel coating) were used for the cell migration assay (Merzak et al.,
1994; Bourguignon et al., 1998b, 2000). SP-1 cells transfected with various
Tiam1-related cDNAs (e.g., full-length Tiam1 cDNA, HA-tagged C1199
Tiam1 cDNA, or GFP-tagged Tiam1 fragment cDNA, or HA-tagged
C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA [cotransfec-
tion], or vector alone) (z1024 cells/well in PBS, pH 7.2, untreated or
treated with cytochalasin D [20 mg/ml] or DMSO alone) were placed in
the upper chamber of the transwell unit. The growth medium containing
high glucose DME supplemented by 10% FBS was placed in the lower
chamber of the transwell unit. After an 18-h incubation at 378C in a hu-
midified 95% air/5% CO2 atmosphere, cells on the upper side of the filter
were removed by wiping with a cotton swap. Cell migration and invasion
processes were determined by measuring the cells that migrate to the
lower side of the polycarbonate filters by standard cell number counting
methods as described previously (Merzak et al., 1994; Zhu and Bour-
guignon, 2000). Each assay was set up in triplicate and repeated at least
five times. All data were analyzed statistically by t test and statistical sig-
nificance was set at P , 0.01.
Results
Identification of the GEF, Tiam1 in Breast Tumor
Cells (SP-1 Cells)
Rho GTPases such as Rac1 become activated when bound
GDP is exchanged for GTP by a process catalyzed by
GEFs such as Tiam1 (Habets et al., 1994). A Tiam1 tran-
script has been detected previously in breast cancer cells
(Habets et al., 1995). In this study, we have analyzed
Tiam1 expression (at the protein level) in SP-1 breast tu-
mor cells. Immunoblot analysis, using anti-Tiam1 antibody
designed to recognize the specific epitope located at the
COOH terminus of Tiam1 molecule, reveals a single
polypeptide (z200 kD; Fig. 1, lane 1). This 200-kD Tiam1-
like molecule, expressed in SP-1 cells, is very similar to the
Tiam1 detected in COS-7 cells that were transiently trans-
fected with the full-length Tiam1 cDNA (Fig. 1, lane 2) or
NH2 terminally truncated C1199 Tiam1 cDNA (Fig. 1,
lane 3 revealing primarily C1199 Tiam1 [160 kD] and a
low level of endogenous Tiam1 [200 kD]). We believe that
the Tiam1 detected in SP-1 cells or COS-7 transfectants,
revealed by anti-Tiam1–mediated immunoblot, is specific
since no protein is detected in these cells using preimmune
rabbit IgG (Fig. 1, lanes 4–6).
To confirm that the Tiam1-like molecule functions as a
GDP/GTP exchange factor (or a GDP-dissociation stimu-
lator protein) for Rac1, we have isolated Tiam1 from SP-1
cells using anti-Tiam1–conjugated Sepharose beads. Our
results indicate that SP1’s Tiam1 activates GDP/GTP ex-
change on GST-Rac1 (Fig. 2 A, a) and, to a lesser extent,
on GST-Cdc42 (Fig. 2 A, b) and GST-RhoA (Fig. 2 A, c).
The initial onset of the exchange reaction on GST-Rac1
Figure 1. Detection of
Tiam1 expression in SP-1
cells or COS-7 transfectants.
SP-1 and COS-7 cells, which
were transfected with the
full-length Tiam1 cDNA
(FL1591) or NH2 terminally
truncated C1199 Tiam1
cDNA or vector alone, were
solubilized in SDS sample
buffer and analyzed by SDS-PAGE and immunoblot as de-
scribed in Materials and Methods. (lane 1) Anti-Tiam1–mediated
immunoblot of SP-1 cells. (lane 2) Anti-Tiam1–mediated immu-
noblot of COS-7 cells transfected with the full-length Tiam1
cDNA (FL1591). (lane 3) Anti-Tiam1–mediated immunoblot of
COS-7 cells transfected with the NH2 terminally truncated C1199
Tiam1 cDNA. (lane 4) Immunoblot of SP-1 cells with preimmune
rabbit serum. (lane 5) Immunoblot of COS-7 cells, which were
transfected with Tiam1 cDNA [FL1591], with preimmune rabbit
serum. (lane 6) Immunoblot of COS-7 cells, which were trans-
fected with the NH2 terminally truncated C1199 Tiam1 cDNA,
with preimmune rabbit serum.
Figure 2. Tiam1-mediated GDP/GTP exchange for Rho GTP-
ases. Purified E. coli-derived GST-tagged GTPases (e.g., Rac1,
Cdc42, or RhoA) were preloaded with GDP. First, 2 pmol Tiam1
that was isolated from SP1 cells or COS-7 transfectants was
added to the reaction buffer containing 20 mM Tris-HCl, pH 8.0,
100 mM NaCl, 10 mM MgCl2, 100 mM AMP-PNP, 0.5 mg/ml
BSA, and 2.5 mM GTP-g–35S (z1,250 Ci/mmol). Subsequently,
2.5 pmol GDP-loaded GST-tagged Rho GTPases (e.g., Rac1,
RhoA, Cdc42, or GST alone) were mixed with the reaction buffer
containing Tiam1 and GTP-g–35S to initiate the exchange reac-
tion at room temperature. At various time points, the reaction of
each sample was terminated by adding ice-cold termination
buffer as described in Materials and Methods. The termination
reactions were filtered immediately through nitrocellulose filters,
and the radioactivity associated with the filters were measured by
scintillation fluid. The amount of GTP-g–35S bound to Tiam1 or
control sample (preimmune serum–conjugated Sepharose beads)
in the absence of Rho GTPases (e.g., Rac1, Cdc42, or RhoA) was
subtracted from the original values. Data represent an average of
triplicates from three to five experiments. SD , 5%. (A) Kinetics
of GTP-g–35S bound to GDP-loaded GST-Rac1 (a), GST-Cdc42
(b), or GST-RhoA (c), or GST alone (d) in the presence of
Tiam1 (isolated from SP-1 cells). (B) The maximal level of GTP-
g–35S bound to GST-Rac1 in the presence of Tiam1 isolated from
SP1 grown in 5% FCS (a, shaded bar) or 20% FCS (a, blank bar);
or the full-length Tiam1 (1,591) isolated from COS-7 transfec-
tants grown in 5% FCS (b, shaded bar) or 20% FCS (b, blank
bar); or the C1199 Tiam1 isolated from COS-7 transfectants
grown in 5% FCS (c, shaded bar), or 20% FCS (c, blank bar); or
Tiam1 isolated from vector-transfected COS-7 cells grown in 5%
FCS (d, shaded bar) or 20% FCS (d, blank bar).
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occurs within 0.5–1 min after the addition of Tiam1, and
the reaction reaches its maximal level z16 min after
Tiam1 addition (Fig. 2 A, a). In contrast, the initial rate of
Tiam1-catalyzed GDP/GTP exchange on Cdc42 (Fig. 2 A,
b) and RhoA (Fig. 2 A, c) appears to be significantly lower
than that detected on Rac1 (Fig. 2 A, a). In the control
samples, the amount of [35S]GTP-g–S associated with GST
alone is found to be significantly decreased (Fig. 2 A, d).
Further analysis indicates that the ability of Tiam1 isolated
from SP-1 cells to promote GDP/GTP exchange on Rac1
(Fig. 2 B, a) is identical to that carried out by the Tiam1
isolated from COS-7 transfected with the full-length
Tiam1 cDNA (Fig. 2 B, b) or NH2 terminally truncated
C1199 Tiam1 cDNA (Fig. 2 B, c). Therefore, we believe
that the Tiam1 in SP-1 cells clearly functions as a GDP/
GTP exchange factor for Rho-like GTPases such as Rac1
GTPase.
We have also noticed that Tiam1 isolated from non-
transfected COS-7 cells grown in the presence of 20% FCS
is capable of catalyzing GDP/GTP exchange on Rac1 at a
much higher level (Fig. 2 B, d, blank bar) than Tiam1 iso-
lated from nontransfected COS-7 cells grown in the pres-
ence of 5% FCS (Fig. 2 B, d, shaded bar). This observation
is consistent with the previous findings that some serum
components play an important role in upregulating the
ability of Tiam1 to promote GDP/GTP exchange on Rac1
(Stam et al., 1998). In SP1 cells (Fig. 2 B, a, blank and
shaded bars) or Tiam1 cDNA–transfected COS-7 cells
(Fig. 2 B, b and c, blank and shaded bars), neither high nor
low serum causes significant changes in the ability of
Tiam1 to catalyze GDP/GTP exchange on Rac1. These
differential serum effects on the activity of Tiam1 isolated
from low or high Tiam1-expressing cells await future in-
vestigation.
Interaction between Tiam1 and the Cytoskeletal 
Proteins, Ankyrin
Certain cytoskeleton proteins, such as ankyrin, are known
to be involved in regulating a variety of cellular activities
(Bennett, 1992; Bennett and Gilligan, 1993; Bourguignon,
1996; Bourguignon et al., 1998a; De Matteis and Morrow,
1998). Both ankyrin1 (ANK1) and ankyrin 3 (ANK3) have
been shown to be expressed in breast tumor cells (Bour-
guignon et al., 1998b, 1999). In this study, we have carried
out anti-ANK1 or anti-ANK3–mediated immunoprecipi-
tation of SP-1 cellular proteins, followed by anti-Tiam1
immunoblot (Fig. 3, A and B, lane 2) and anti-ANK1 (Fig.
3 A, lane 3)/ANK3 (Fig. 3 B, lane 3) immunoblot, respec-
tively. Our results indicate that the Tiam1 band is revealed
in antiankyrin (e.g., ANK1 or ANK3)–mediated immuno-
precipitated materials (Fig. 3, A and B, lane 2). Appar-
ently, Tiam1 is coprecipitated with ANK1 and/or ANK3
(revealed by reblotting with anti-ANK1/ANK3 antibody;
Fig. 3, A and B). In control samples, immunoblotting of
anti-ANK1 or anti-ANK3–immunoprecipitated material
using rabbit preimmune serum (Fig. 3, A and B, lane 1)
does not reveal any protein associated with this material.
Anti-Tiam1–mediated immunoprecipitation of SP-1 cellu-
lar proteins, followed by anti-ANK1 (Fig. 3 A, lane 4) or
anti-ANK3 (Fig. 3 B, lane 4)–mediated immunoblot also
shows that both ANK1 (Fig. 3 A, lane 4) and ANK3 (Fig.
3 B, lane 4) can be coprecipitated with Tiam1 (revealed
by reblotting with anti-Tiam1 antibody; Fig. 3, A and B,
lane 5). In controls, very little material is detected in this
anti-Tiam1–mediated immunocomplex using either nor-
mal mouse IgG (Fig. 3, A and B, lane 6) or rabbit preim-
mune serum–mediated immunoblot (Fig. 3 A, lane 7).
These findings clearly establish the fact that Tiam1 and
ankyrin (e.g., ANK1 and ANK3) are closely associated
with each other as an in vivo complex in breast tumor cells.
Further analyses using an in vitro binding assay
show that 125I-labeled ankyrin (i.e., erythrocyte ankyrin
[ANK1]) binds Tiam1, which was isolated from SP1 cells,
specifically (Fig. 4 A, a). In addition, we have used 125I-
labeled ankyrin to bind purified Tiam1 (isolated from SP-1
cells) on a gel (Fig. 4 B, a). Our data indicate that Tiam1
binds to ankyrin (ANK1; Fig. 4 B, a) directly. In the pres-
ence of an excess amount of unlabeled ankyrin, the bind-
ing between ankyrin and Tiam1 is greatly reduced (Fig. 4,
A and B, b). Other cytoskeletal proteins, such as spectrin,
Figure 3. Detection of Tiam1–ankyrin complex in SP1 cells. SP1
cells (5 3 105 cells) were solubilized by 1% NP-40 buffer and pro-
cessed for antiankyrin or anti-Tiam1–mediated immunoprecipi-
tation, followed by immunoblotting with anti-Tiam1 or anti-
ANK1 (or anti-ANK3) antibody, respectively, as described in
Materials and Methods. (A) Analysis of Tiam1–ANK1 complex
(lane 1). Anti-ANK1–mediated immunoprecipitation followed
by immunoblotting with rabbit preimmune serum. (lanes 2 and 3)
Detection of Tiam1 in the complex by mouse anti-ANK1–medi-
ated immunoprecipitation, followed by immunoblotting with rab-
bit anti-Tiam1 antibody (lane 2) or reblotting with mouse anti-
ANK-1 antibody (lane 3). (lanes 4–7) Detection of ANK1 in the
complex by rabbit anti-Tiam1–mediated immunoprecipitation,
followed by immunoblotting with mouse anti-ANK1 antibody
(lane 4) or reblotting with rabbit anti-Tiam1 antibody (lane 5), or
peroxidase-conjugated normal mouse IgG (lane 6) or peroxi-
dase-conjugated rabbit preimmune IgG (lane 7). (B) Analysis of
Tiam1-ANK3 complex: (lane 1) anti-ANK3-mediated immuno-
precipitation followed by immunoblotting with rabbit preim-
mune serum. (lanes 2 and 3) Detection of Tiam1 in the complex
by mouse anti-ANK3-mediated immunoprecipitation, followed
by immunoblotting with rabbit anti-Tiam1 antibody (lane 2) or
reblotting with mouse anti-ANK-3 antibody (lane 3). (lanes 4–7)
Detection of ANK3 in the complex by rabbit anti-Tiam1–medi-
ated immunoprecipitation, followed by immunoblotting with
mouse anti-ANK3 antibody (lane 4) or reblotting with rabbit
anti-Tiam1 antibody (lane 5), or peroxidase-conjugated normal
mouse IgG (lane 6), or peroxidase-conjugated rabbit preimmune
IgG (lane 7).
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do not interfere with ankyrin binding to Tiam1 (Fig. 4, A
and B, c). However, the precise functional domain of
ankyrin involved in Tiam1 binding remains to be deter-
mined.
The NH2-terminal region of ankyrin’s membrane bind-
ing domain (Fig. 5 A, a) is comprised of a tandem array of
24 ankyrin repeats (so-called ankyrin repeat domain,
ARD; Fig. 5 A, b). The question of whether the mem-
brane-binding domain of ankyrin (in particular, ARD) is
involved in Tiam1 binding is now addressed in this study.
First, the pGEX-2TK recombinant plasmid encoding ARD
(NH2-terminal portion of ankyrin, from amino acids 1 to
834) was constructed with a GST tag and expressed in E.
coli (Zhu and Bourguignon, 2000). The purified GST-
tagged ARD fusion protein is expressed as a 116-kD pro-
tein (Fig. 5 B, lane 1). After the removal of GST tag by
thrombin digestion, the ARD itself is found to be an 89-kD
polypeptide (Fig. 5 B, lane 2), which is similar to the 89-kD
ARD obtained by enzymatic digestion of erythrocyte
ankyrin (Davis and Bennett, 1990).
Next, we have used the ARD fragment of ANK3 (GST-
ARD) and purified Tiam1 to identify the exact Tiam1
binding site(s) on the ankyrin molecule. Specifically, we
have tested the binding of Tiam1 to 125I-labeled intact
erythrocyte ankyrin (ANK1), or 125I-labeled GST-ARD
fragment of ANK3, under equilibrium binding conditions.
Scatchard plot analyses indicate that intact erythrocyte
ankyrin (ANK1) binds to Tiam1 at a single site (Fig. 5 C)
with high affinity (an apparent dissociation constant [Kd]
of z0.72 nM). This ankyrin–Tiam1 binding interaction is
comparable in affinity to Tiam1 binding (Kd z1.42 nM)
to ANK3’s ARD fragment (Fig. 5 D). These findings
strongly support the notion that ankyrin (in particular, the
ARD) is involved in the Tiam1 binding site.
Determination of Tiam1’s Ankyrin-binding Domain
Previous studies indicate that Tiam1’s NH2-terminal pleck-
strin homology (PHn) domain and an adjacent protein in-
teraction domain (i.e., a sequence between amino acids
393 and 738 of Tiam1; Fig. 6 A, a–c) is required for the ac-
tivation of Rac1 signaling pathways leading to membrane
ruffling and c-Jun NH2-terminal kinase activation (Michiels
Figure 4. Binding interaction between Tiam1 and the cytoskele-
tal protein ankyrin. (A) Tiam1 (isolated from SP-1 cells) bound
to the anti-Tiam1 immunobeads were incubated with 125I-labeled
ankyrin (5,000 cpm/ng protein) in the absence (a) or the presence
of 100-fold excess of unlabeled ankyrin (b) or spectrin (c). After
binding, the immunobeads were washed extensively in binding
buffer and the bead-bound radioactivity was estimated. (B) Au-
toradiogram of 125I-labeled ankyrin binding to a polyacrylamide
gel containing purified Tiam1 (isolated from SP-1 cells) in the ab-
sence (a) or the presence of 100-fold excess of unlabeled ankyrin
(b) or spectrin (c).
Figure 5. Ankyrin structure and ankyrin repeat domain (ARD)
fusion protein. (A, a) Schematic illustration of functional do-
mains in full-length ankyrin: ankyrin repeat domain (ARD),
spectrin binding domain (SBD), and regulatory domain (RD).
(A, b) ARD cDNA was constructed according to the strategy
described in Materials and Methods. This ARD cDNA construct
encodes for the NH2-terminal region of the ankyrin membrane
binding domain with a tandem array of 24 ankyrin repeats. (B) A
Coomassie blue stain of the 116-kD GST-ARD fusion protein
purified by affinity column chromatography (lane 1), and the
89-kD ARD (lane 2) after the removal of GST by thrombin di-
gestion. (C and D) Scatchard plot analyses of the equilibrium
binding between 125I-labeled ankyrin and Tiam1. Various con-
centrations of 125I-labeled ankyrin (e.g., intact erythrocyte
ankyrin [ANK1] or ARD) were incubated with purified Tiam1-
coupled beads at 48C for 4 h. After binding, beads were washed
extensively in binding buffer and the bead-bound radioactivity
was counted. As a control, 125I-labeled ankyrin or 125I-labeled
ARD was also incubated with uncoated beads to determine the
binding observed because of the nonspecific binding of various
ligands. Nonspecific binding, which represented z20% of the to-
tal binding, was always subtracted from the total binding. Our
binding data are highly reproducible. Scatchard plot analysis of
the equilibrium binding data between 125I-labeled intact erythro-
cyte ankyrin (ANK1) and Tiam1 (C); and Scatchard plot analysis
of the equilibrium binding data between 125I-labeled ARD and
Tiam1 (D).
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et al., 1997; Stam et al., 1997). Using a 49-kD E. coli–
derived CBP-tagged Tiam1 fragment (i.e., amino acids
393–738 of Tiam1; Fig. 6 B, lane 1) and an in vitro binding
assay (Fig. 6 C), we have detected a specific binding inter-
action between the Tiam1 fragment and ankyrin (Fig. 6 C,
a) and ARD (Fig. 6 C, b) but not the spectrin binding do-
main of ankyrin (Fig. 6 C, c) or spectrin (Fig. 6 C, d).
Furthermore, we have evaluated the binding interaction
between GST-ARD fusion protein and the recombinant
C1199 Tiam1 (NH2 terminally truncated Tiam1; Fig. 6 D).
First, glutathione-Sepharose beads containing GST-ARD
were incubated with C1199 Tiam1 in the absence (Fig. 6,
D and E, lane 1) or the presence of an excess amount of
Tiam1 fragment (Fig. 6, D and E, lane 2). In controls,
C1199 Tiam1 was also added to Sepharose beads contain-
ing GST alone (Fig. 6, D and E, lane 3). After binding, the
GST fusion protein was eluted with its associated C1199
Tiam1 using a buffer containing glutathione. The amount
of eluted GST fusion protein and C1199 Tiam1 was deter-
mined by SDS-PAGE and Coomassie blue staining (Fig. 6
E) followed by densitometric scanning analyses (Fig. 6 D).
Our results indicate that the stoichiometry of ARD–C1199
Tiam1 interaction is z1:1 (Fig. 6 D, lane 1, and Fig. 6 E,
lane 1, a and b). In the presence of an excess amount
(z100-fold) of recombinant Tiam1 fragment, the binding
between ankyrin ARD and C1199 Tiam1 is significantly
reduced (Fig. 6, D and E, lane 2, a and b). The control
beads containing GST alone fail to bind C1199 Tiam1 (Fig.
6 D, lane 3, and Fig. 6 E, lane 3, a and b). These observa-
tions suggest that ankyrin ARD directly interacts with
Tiam1, and that the ankyrin-binding domain (ARD)–con-
taining Tiam1 fragment act as a potent competitive inhibi-
tor of Tiam1 binding to ankyrin in vitro.
Protein sequence analyses show that Tiam1 contains
the sequence 717GEGTDAVKRS727L (in mouse), or
717GEGTEAVKRS727L (in human) that shares a great
deal of sequence homology with the ankyrin-binding do-
main of the cell adhesion receptor, CD44 family (Lokesh-
war et al., 1994; Zhu and Bourguignon, 1998). To test
whether the sequence GEGTDAVKRSL of Tiam 1 pro-
tein is in fact involved in ankyrin binding, we have exam-
ined the ability of an 11–amino acid synthetic peptide,
identical to GEGTDAVKRSL, to bind various cytoskele-
tal proteins. As shown in Table I, this synthetic peptide
binds specifically to intact ankyrin and the ARD, but not
the SBD of ankyrin or other cytoskeletal proteins such as
spectrin. Control peptides, containing the scrambled se-
quence (GRATLEGSDKV) with the same amino acid
composition as that of the synthetic peptide or another
peptide (GTIKRAPFLGP) from a different region (i.e.,
the sequence between amino acids 399 and 409) of Tiam1,
fail to bind any cytoskeletal proteins tested (Table I).
We have also used the synthetic peptide corresponding
to Tiam1’s amino acid 717–727 sequence to compete for
the binding of purified Tiam1 to ankyrin. As shown in Fig.
7 A (c), the synthetic peptide competes effectively with
Tiam1 to bind ankyrin with an apparent inhibition con-
stant (Ki) z0.5 nM. However, control peptides such as
GRATLEGSDKV (Fig. 7 A, a) or GTIKRAPFLGP (Fig.
7 A, b) do not compete at all with Tiam1 in ankyrin bind-
ing. These results suggest that the amino acid 717–727 se-
quence of Tiam1 is a critical part of the ankyrin-binding
domain of Tiam1. Finally, we have constructed an HA-
tagged C1199 Tiam1 deletion mutant lacking the ankyrin
binding sequence, amino acids 717–727 (designated as
C1199 Tiam1D717-727; Fig. 7 B, b). The truncated C1199
Figure 6. Properties of Tiam1 and Tiam1 mutant proteins. (A, a)
The full-length Tiam1 contains DH, dbl homology domain;
DHR, discs-large homology domain; two pleckstrin homology
(PH) domains (including the NH2-terminal PH [PHn] and the
COOH-terminal PH [PHc]). (A, b) The NH2 terminally trun-
cated C1199 Tiam1 encodes the COOH-terminal 1,199 amino ac-
ids. (A, c) The Tiam1 fragment encodes the sequence between
amino acids 393 and 738. (B) Characterization of Tiam1 fragment
(amino acids 393–738) fusion proteins. Coomassie blue staining
of E. coli–derived CBP-Tiam1 fragment fusion protein purified
by calmodulin affinity column chromatography (lane 1); and
GFP-tagged Tiam1 fragment fusion purified by anti-GFP–conju-
gated affinity column chromatography (lane 2). (C, a) Binding of
125I-Tiam1 fragment to ankyrin. (C, b) Binding of 125I-Tiam1 frag-
ment to ARD. (C, c) Binding of 125I-Tiam1 fragment to the spec-
trin binding domain of ankyrin. (C, d) Binding of 125I-Tiam1 frag-
ment to spectrin. (D and E) Binding analysis between GST-ARD
and the recombinant C1199 Tiam1 in vitro. In each reaction, glu-
tathione-Sepharose bead slurry containing GST-ARD or GST
alone was suspended in the binding buffer (20 mM Tris-HCl, pH
7.4, 150 mM NaCl, 0.1% BSA, and 0.05% Triton X-100). Purified
C1199 Tiam1 (0.5–1.0 mg) was added to the bead suspension in
the absence or the presence of an excess amount of CBP-tagged
Tiam1 fragment (100 mg) at 48C for 4 h. After binding, the GST
fusion protein was eluted with its associated C1199 Tiam1 using
150 ml of 50 mM Tris-HCl, pH 8.0, buffer containing glutathione.
The amount of eluted GST fusion protein and C1199 Tiam1 was
determined by SDS-PAGE and Coomassie blue staining, fol-
lowed by densitometric scanning using a software NIH Image
V1.54. The amount of ARD (mol) per C1199 Tiam1 (mol) was
calculated. Values represent relative binding abilities averaged
from three experiments 6 SEM. (D) The amount of C1199
Tiam1 (mol) associated with GST-ARD (mol) was measured in
the absence (lane 1) or the presence of the recombinant Tiam1
fragment (lane 2) or C1199 Tiam1 associated with GST-coated
beads (lane 3) using SDS-PAGE and Coomassie blue staining
followed by densitometric analyses. (E) Coomassie blue staining
of C1199 Tiam1 associated with GST-ARD in the absence (lane
1) or the presence of recombinant Tiam1 fragment (lane 2) or
C1199 Tiam1 associated with GST-coated beads (lane 3).
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Tiam1 717-727 cDNA (Fig. 7 B, b) and the wild-type
C1199 Tiam1 (Fig. 7 B, a) were transiently transfected into
SP-1 cells. Our results indicate that both the C1199
Tiam1D717-727 mutant (Fig. 7 C, lane 3) and the wild-type
C1199 Tiam1 (Fig. 7 C, lane 2) are expressed as a 160-kD
polypeptide in SP-1 transfectants using anti-HA–mediated
immunoblotting. No protein band was detected in vector-
transfected SP-1 cells (Fig. 7 C, lane 1). In vitro binding
data reveal that there is a strong binding interaction be-
tween ankyrin and HA-tagged C1199 (Fig. 7 D, b). In con-
trast, the HA-tagged C1199 Tiam1D717-727 mutant pro-
tein isolated from SP-1 transfectants displays a drastic
reduction (z90–95% inhibition) in ankyrin-binding ability
(Fig. 7 D, c) compared with the HA-tagged wild-type
C1199 Tiam1 (Fig. 7 D, b). No ankyrin binding is observed
in materials associated with anti-HA beads using cell ly-
sate isolated from vector-transfected cells (Fig. 7 D, a).
These findings suggest that the amino acid 717–727 region
is critical for the interaction of Tiam1 with ankyrin.
Most importantly, we have found that the binding of
ankyrin (e.g., erythrocyte ankyrin [ANK1], Fig. 8 A, or
ANK3’s ARD, Fig. 8 B) to Tiam1 significantly increases
the GDP/GTP exchange activity of Rac1 GTPase as com-
pared with untreated Tiam1-mediated Rac1 activation
(Fig. 8 C). The SBD of ankyrin or other cytoskeletal pro-
teins, such as spectrin, fails to stimulate Tiam1-mediated
GDP/GTP exchange on Rac1 GTPase (data not shown).
Therefore, we believe that ankyrin binding to Tiam 1 plays
a pivotal role in the upregulation of Tiam 1-mediated
GDP/GTP exchange activity of Rho-like GTPases (e.g.,
Rac1).
Effect of Tiam1 or the Tiam1 Fragment on Rac1 
Activation, Tumor Cell Invasion, and Migration
Previous studies have indicated that both ankyrin and
Tiam1 are closely associated with certain tumor-specific
behaviors, characterized by an invadopodia structure (or
membranous projections) during epithelial tumor cell mi-
Table I. Binding of 125I-Labeled Cytoskeletal Proteins to 
Synthetic Peptides
nM 3 CPM Bound
Binding to GEGTDAVKRSL
(the sequence between amino acids 717 and 727 
of Tiam1)
125I-Labeled ankyrin 15,260 6 120
125I-Labeled ARD 14,560 6 105
125I-Labeled ankyrin’s spectrin binding 
domain
 770 6 22
125I-Labeled spectrin  850 6 34
Binding to GRATLEGSDKV
(the scrambled sequence)
125I-Labeled ankyrin 1,020 6 36
125I-Labeled ARD  920 6 29 
125I-Labeled ankyrin’s spectrin binding 
domain
 901 6 24
125I-Labeled spectrin  996 6 27
Binding to GTIKRAPFLGP
(the sequence between amino acids 399 and 409 
of Tiam1)
125I-Labeled ankyrin  899 6 23
125I-Labeled ARD  854 6 17
125I-Labeled ankyrin’s spectrin binding 
domain
 842 6 19
125I-Labeled spectrin  863 6 20
125I-labeled cytoskeletal proteins (e.g., intact ankyrin [100 ng] or ARD [100 ng] or
spectrin binding domain of ankyrin [100 ng] or spectrin [100 ng] were incubated with
nitrocellulose discs coated with either the synthetic peptide GEGTDAVKRSL
(corresponding to the sequence between amino acids 717 and 727 of Tiam1), or
the scrambled peptide GRATLEGSDKV, or another Tiam1-related peptide,
GTIKRAPFLGP (corresponding to the sequence between amino acids 399 and 409 of
Tiam1) at 48C for 4 h as described in Materials and Methods. As a control, the
radiolabeled ligands including  125I-labeled ankyrin, 125I-labeled ARD, and 125I-labeled
spectrin were also incubated with uncoated beads to determine the binding observed
because of the nonspecific binding of various ligands. Nonspecific binding, which
represented z20% of the total binding, was always subtracted from the total binding.
Figure 7. Identification of the ankyrin binding domain of Tiam1.
(A) 125I-labeled Tiam1 was incubated with ankyrin-coated beads
in the presence of various concentrations of unlabeled synthetic
peptide (GEGTDAVKRSL, corresponding to the sequence be-
tween amino acids 17 and 727 of Tiam1) (c), or the scrambled se-
quence (GRATLEGSDKV; a), or another Tiam1-related pep-
tide (GTIKRAPFLGP, corresponding to the sequence between
amino acids 399 and 409 of Tiam1; b) as described in Materials
and Methods. The specific binding observed in the absence of
any of the competing peptides is designated as 100%. The results
represent an average of duplicate determinations for each con-
centration of the competing peptide used. (B) Schematic illustra-
tion of the in vitro mutagenesis approach used in this study. Both
C1199 Tiam1 (a) and C1199 Tiam1 717-727 (lacking the sequence
between amino acids 17 and 727; b) were constructed according
to the strategy described in Materials and Methods. (C) Anti-
HA–mediated immunoblot of SP-1 cells transiently transfected
with vector alone (lane 1), or HA-tagged C1199 Tiam1 cDNA
(lane 2), or HA-tagged C1199 Tiam1 717-727 cDNA (lane 3). (D)
The amount of 125I-ankyrin binding to anti-HA–mediated immu-
noprecipitates isolated from SP-1 cells transfected with vector
alone (a), or HA-tagged C1199 Tiam1 cDNA (b), or HA-tagged
C1199 Tiam1 717-727 cDNA (c).
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gration (Bourguignon et al., 1998a,b, 2000; Zhu and Bour-
guignon, 2000). In this study, using double immunolabel-
ing staining, we have observed that both ankyrin (Fig. 10
A) and Tiam1 (Fig. 10 B) are colocalized in the plasma
membrane and long projections of SP1 cells (Fig. 10 C).
Furthermore, we have transiently transfected breast tumor
cells (e.g., SP-1 cells) with HA-tagged NH2 terminally
truncated C1199 Tiam1 cDNA. Our results show that the
C1199 Tiam1 is expressed as a 160-kD protein (Fig. 9 B, a)
detected by anti-HA–mediated immunoblot in SP1 cells.
No protein band was detected in vector-transfected SP1
cells by anti-HA–mediated immunoblotting (Fig. 9 A, a).
Double immunofluorescence staining data show that anky-
rin (Fig. 10 D) and C1199 Tiam1 (Fig. 10 E) are also colo-
calized on the plasma membrane–related long projections
of these C1199 Tiam1 cDNA–transfected cells (Fig. 10 F).
Furthermore, we have demonstrated that transfection of
SP1 cells with C1199 Tiam1 cDNA stimulates ankyrin-
associated Tiam1-catalyzed GDP/GTP exchange on Rac1
(Fig. 11 a), and induces a significant amount of increase in
breast tumor cell invasion (Table II, A) and migration
(Table II, B) as compared with vector-transfected SP1
transfectants (Fig. 11 b and Table II, A and B). These re-
sults are consistent with previous findings indicating that
transfection of NIH3T3 cells with the NH2 terminally trun-
cated C1199 Tiam1 cDNA confers potent oncogenic prop-
erties (Van Leeuwen et al., 1995).
Treatment of SP1 cells (e.g., untransfected or trans-
fected cells) with certain agents (e.g., cytochalasin D, a mi-
crofilament inhibitor) causes a remarkable inhibition of
tumor cell invasion (Table II A) and migration (Table II
B). Tiam1-Rac1 signaling initiates oncogenic cascades in-
cluding c-Jun kinase (JNK) activation, which triggers gene
transcription through c-jun and promotes cell transforma-
tion (Michiels et al., 1995, 1997). In addition, Tiam1-acti-
vated Rac1 stimulates the novel family of serine/threonine
kinases, p-21 activated kinases (Manser et al., 1994; Knaus
et al., 1995; Bagrodia and Cerione, 1999), which mediates
actin assembly and induce the formation of membrane ruf-
fling and lamellipodia (membrane projections). In fact,
cytoskeleton-associated membrane projections are often
tightly linked to matrix degrading enzymes during breast
tumor cell invasion and migration (Bourguignon et al.,
1998b). These findings suggest that Tiam1-Rac1 signaling
and selective effector(s) play an important role in promot-
ing certain gene expression required for cellular trans-
formation and the upregulation of cytoskeletal changes
needed for tumor cell invasion and migration. Identifica-
Figure 8. Stimulation of Tiam1-catalyzed GDP/GTP exchange
activity by ankyrin. Purified E. coli–derived GST-tagged GTP-
ases (e.g., Rac1, Cdc42, or RhoA) was preloaded with GDP. Sub-
sequently, 2 pmol of Tiam1 (isolated from untransfected or trans-
fected cells according to the procedures described above) was
preincubated with no ankyrin or ankyrin (e.g., intact ankyrin or
ARD; 1 mg/ml), followed by adding to the reaction buffer con-
taining 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM MgCl2,
100 mM AMP-PNP, 0.5 mg/ml BSA, and 2.5 mM GTP-g–35S
(z1,250 Ci/mmol). Subsequently, 2.5 pmol of GDP-loaded GST-
tagged Rho GTPases (e.g., Rac1, Rac1, or Cdc42) was mixed
with the reaction buffer containing Tiam1 and GTP-g–35S to
initiate the exchange reaction at room temperature. At various
time points, the reaction of each sample was terminated by add-
ing ice-cold termination buffer containing 20 mM Tris-HCl, pH
8.0, 100 mM NaCl, and 10 mM MgCl2 as described in Materials
and Methods. The termination reactions were filtered immedi-
ately through nitrocellulose filters, and the radioactivity associ-
ated with the filters was measured by scintillation fluid. The
amount of GTP-g–35S bound to Tiam1 or control sample (preim-
mune serum–conjugated Sepharose beads) in the absence of Rho
GTPases (e.g., Rac1, Cdc42, or RhoA) was subtracted from the
original values. Data represent an average of triplicates from
three to five experiments. SD , 5%. (A–C) Kinetics of GTP-g–35S
bound to GDP-loaded GST-Rac1 by Tiam1 (isolated from SP-1
cells) in the absence (C) or in the presence of ankyrin, e.g., intact
erythrocyte ankyrin (ANK1; A) or ARD fragment (B).
Figure 9. Transfection of SP1 cells with HA-tagged C1199 Tiam1
cDNA (A) or GFP-tagged Tiam1 fragment cDNA (B) or
cotransfection of HA-tagged C1199 Tiam1 cDNA and GFP-
tagged Tiam1 fragment cDNA (C). Detection of C1199 Tiam1
expression by anti-HA–mediated immunoblot in HA-tagged
C1199 Tiam1 cDNA–transfected cells (B, a) or in vector-trans-
fected cells (A, a). Detection of Tiam1 fragment expression by
anti-GFP–mediated immunoblot in GFP-tagged Tiam1 fragment
cDNA–transfected cells (C, b) or vector-transfected cells (A, b).
Detection of coexpression of C1199 Tiam1 and Tiam1 fragment
by immunoblotting of cells (cotransfected with HA-tagged C1199
Tiam1 cDNA and GFP-tagged Tiam1 fragment cDNA) with
anti-HA antibody (D, a) and anti-GFP antibody (D, b), respec-
tively. In controls, no signal was detected in HA-tagged C1199
Tiam1 cDNA–transfected cells or GFP-tagged Tiam1 fragment
cDNA–transfected cells using anti-GFP (B, b) or anti-HA (C, a)–
mediated immunoblotting, respectively.
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tion of immediate downstream targets for ankyrin-medi-
ated Tiam1-Rac1 signaling is currently under investigation
in our laboratory.
We have also found that SP1 cells transfected with GFP-
tagged Tiam1 fragment cDNA express a 68-kD protein as
detected by anti-GFP antibody (Fig. 6 B, lane 2; Fig. 9 C,
b). In vector-transfected SP1 cells, we are not able to de-
tect any protein band by anti-GFP–mediated immunoblot-
ting (Fig. 9 A, b). Double immunofluorescence staining
shows that both ankyrin (Fig. 10 G) and the GFP-tagged
Tiam1 fragment (Fig. 10 H) are colocalized in the cell
membranes in SP1 transfectants (Fig. 10 I). We believe
that the ankyrin staining detected in these SP1 transfec-
tants, revealed by antiankyrin-mediated immunostaining,
Figure 10. Double immunofluorescence staining of ankyrin and Tiam1 in untransfected SP1 cells or SP1 transfectants. SP1 cells (un-
transfected or transfected with HA-tagged C1199 Tiam1 cDNA or GFP-tagged Tiam1 fragment cDNA or cotransfected with HA-
tagged C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA) were fixed by 2% paraformaldehyde. Subsequently, cells were
rendered permeable by ethanol treatment and stained with various immunoreagents as described in Materials and Methods. (A–C) Rh-
labeled anti-ANK3 staining (A) FITC-anti-Tiam1 staining (B) and colocalization of ankyrin and Tiam1 (C) in untransfected SP1 cells.
(D–F) Rh-labeled anti-ANK3 staining (D) FITC-anti-HA–labeled C1199 Tiam1 staining (E), and colocalization of ankyrin and C1199
Tiam1 (F) in HA-tagged C1199 Tiam1 cDNA–transfected SP1 cells. (G–I) Rh-labeled anti-ANK3 staining (G), GFP-tagged Tiam1 frag-
ment (H), and colocalization of ankyrin and Tiam1 fragment (I) in GFP-tagged Tiam1 fragment cDNA–transfected SP1 cells. (a–c) Rh-
labeled normal mouse IgG staining (a), GFP-tagged Tiam1 fragment (b), and colocalization of normal mouse IgG and Tiam1 fragment
(c) in GFP-tagged Tiam1 fragment cDNA–transfected SP1 cells. (J–L) Rh-labeled anti-HA staining of C1199 Tiam1 (J), GFP-tagged
Tiam1 fragment (K), and colocalization of C1199 and Tiam1 fragment (L) in SP1 cells cotransfected with HA-tagged C1199 cDNA and
GFP-tagged Tiam1 fragment cDNA. (d–f) Rh-labeled anti-ANK3 staining (d), GFP-tagged Tiam1 fragment (e), and colocalization of
ankyrin and Tiam1 fragment (f) in SP1 cells cotransfected with HA-tagged C1199 cDNA and GFP-tagged Tiam1 fragment cDNA.
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is specific since no label (Fig. 10 a) is detected in these
GFP-Tiam1 fragment–overexpressed cells (Fig. 10 b) us-
ing normal mouse IgG (Fig. 10 a). No colocalization (Fig.
10 c) of normal mouse IgG (Fig. 10 a) and GFP-Tiam1
fragment (Fig. 10 b) is observed in these transfectants.
Moreover, we have demonstrated that overexpression
of the GFP-tagged Tiam1 fragment in SP1 transfectants
downregulates ankyrin-associated Tiam1-Rac1 signaling
(Fig. 10 d), tumor cell invasion (Table II, A), as well as cell
migration (Table II, B).
Finally, cotransfection of SP1 cells with HA-tagged
C1199 Tiam1 cDNA and GFP-tagged Tiam1 fragment
cDNA was carried out. Using anti-HA or anti GFP-medi-
ated immunoblotting technique, we have detected coex-
pression of both C1199 Tiam1 (Fig. 9 D, a) and Tiam1
fragment (Fig. 9 D, b) in SP1 transfectants. In controls, no
signal was detected in HA-tagged C1199 Tiam1 cDNA–
transfected cells or GFP-tagged Tiam1 fragment cDNA–
transfected cells using anti-GFP (Fig. 9 B, b) or anti-HA
(Fig. 9 C, a)–mediated immunoblotting, respectively. Fur-
thermore, immunocytochemical staining results show that
ankyrin (Fig. 10 d) and the GFP-tagged Tiam1 fragment
(Fig. 10 e) are colocalized (Fig. 10 f) in the plasma mem-
branes of SP1 transfectants. In contrast, C1199 Tiam1 (Fig.
10 J) fails to display plasma membrane localization. Con-
sequently, the level of colocalization (Fig. 10 L) between
C1199 Tiam1 (Fig. 10 J) and Tiam1 fragment (Fig. 10 K) is
greatly reduced. In addition, it is noted that no significant
stimulation of long membrane projections was observed in
these transfectants (Fig. 10, J–L and d–f). Other tumor-
specific behaviors such as Tiam1-Rac1 activation (Fig. 11
c) and cytoskeleton-mediated breast tumor cell invasion
(Table II, A) and migration (Table II B) are also greatly
inhibited. These findings suggest that the ankyrin-binding
domain-containing Tiam1 fragment acts as a dominant
negative mutant that effectively competes for ankyrin
binding to C1199 Tiam1 in vivo and blocks ankyrin-regu-
lated Tiam1 function associated with tumor-specific phe-
notypes.
Discussion
The invasive phenotype of breast tumors, determined by
Figure 11. Kinetics of GTP-g–35S bound to GDP-loaded GST-
Rac1 in the presence of ankyrin-associated Tiam1 isolated from
SP-1 cells: transfected with HA-tagged C1199 Tiam1 cDNA (a)
or GFP-tagged Tiam1 fragment cDNA (d); or cotransfected with
HA-tagged C1199 Tiam1 cDNA plus GFP-tagged Tiam1 frag-
ment cDNA (c) or vector alone (b). Purified E. coli–derived
GST-tagged GTPases (e.g., Rac1, Cdc42, or RhoA) were pre-
loaded with GDP. First, 2 pmol ankyrin-associated Tiam1 iso-
lated from various SP1 transfectants was added to the reaction
buffer containing 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM
MgCl2, 100 mM AMP-PNP, 0.5 mg/ml BSA, and 2.5 mM GTP-
g–35S (z1,250, Ci/mmol). Subsequently, 2.5 pmol GDP-loaded
GST-tagged Rho GTPases (e.g., Rac1, RhoA, Cdc42 or GST
alone) were mixed with the reaction buffer containing ankyrin-
associated Tiam1 and GTP-g–35S to initiate the exchange reac-
tion at room temperature. At various time points, the reaction of
each sample was terminated by adding ice-cold termination
buffer as described in Materials and Methods. The termination
reactions were filtered immediately through nitrocellulose filters,
and the radioactivity associated with the filters were measured by
scintillation fluid. The amount of GTP-g–35S bound to Tiam1 or
control sample (preimmune serum–conjugated Sepharose beads)
in the absence of Rho GTPases (e.g., Rac1, Cdc42, or RhoA) was
subtracted from the original values. Data represent an average of
triplicates from three to five experiments. SD , 5%.
Table II. Measurement of Tumor Cell Invasion and Migration
Cell invasion* Percent control‡
Cells
DMSO-
treated
Cytochalasin 
D–treated
In vitro cell invasion
Untransfected cells (control) 100 22
Vector-transfected cells 96 24
Tiam1 fragment 
cDNA–transfected cell
95 20
C1199 Tiam 1 
cDNA–transfected cells
155 50
C1199 Tiam1 cDNA and Tiam1 
fragment cDNA–cotransfected 
cells
90 17
In vitro cell migration
Untransfected cells (control) 100 20
Vector-transfected cells 98 23
Tiam1 fragment
cDNA–transfected cell
93 22
C1199 Tiam1 
cDNA–transfected cells
158 55
C1199 Tiam1 cDNA and Tiam1 
fragment cDNA–cotransfected 
cells 88 14
*SP1 cells (z104 cells/well in  PBS, pH 7.2), in the presence or absence of 20 mg/ml
cytochalasin D (dissolved in DMSO) or DMSO alone, were placed in the upper
chamber of the transwell unit. In some cases, SP1 cells were transfected with either
HA-tagged C1199 Tiam1 cDNA or GFP-tagged Tiam1 fragment cDNA or HA-tagged
C1199 Tiam1 cDNA plus GFP-tagged Tiam1 fragment cDNA, or vector alone. After
an 18-h incubation at 378C in a humidified 95% air/5% CO2 atmosphere, cells on the
upper side of the filter were removed by wiping with a cotton swap. Cell migration
processes were determined by measuring the cells that migrate to the lower side of the
polycarbonate filters containing serum by standard cell number counting assays as
described in Materials and Methods. Each assay was set up in triplicate and repeated at
least three times. All data were analyzed statistically by t test and statistical
significance was set at P , 0.01. In these experiments z30–40% of input cells (z104
cells/well) undergo in vitro cell invasion and migration in the control samples.
‡The values expressed in this table represent an average of triplicate determinations of
three to five experiments with an SD less than 6 5%.
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characteristics such as tumor cell motility and membrane
perturbations, is clearly linked to cytoskeletal function. For
example, recent studies have shown that certain metasta-
sis-specific molecules (e.g., CD44v3,8–10 isoform [Bour-
guignon et al., 1998b, 1999] and its associated matrix me-
talloproteinase, MMP-9 [Bourguignon et al., 1998b; Yu and
Stamenkovic, 1999], as well as Rho kinase [Bourguignon
et al., 1999]) are closely associated with the cytoskeleton
during tumor cell function. To further examine the regula-
tory mechanism(s) involved in cytoskeleton-mediated on-
cogenic signaling leading to tumor cell invasion and migra-
tion, we have focused on GEFs (the Dbl or DH family),
such as Tiam1, which are known to display oncogenic ca-
pability and function as upstream activators of Rho-like
GTPases (e.g., Rac1 or Cdc42; Woods et al., 1991; Habets
et al., 1994; Michiels et al., 1995; Nobes and Hall, 1995; Van
Leeuwen et al., 1995). In breast tumor cells, such as SP-1
cells, Tiam1 is detected as a 200-kD protein (Fig. 1), which
is similar to the Tiam1 described in other cell types
(Woods and Bryant, 1991; Michiels et al., 1995; Nobes and
Hall, 1995; Van Leeuwen et al., 1995, 1997; Hordijk et al.,
1997; Stam et al., 1997; Bourguignon et al., 2000). Tiam1,
isolated from SP-1 cells, is also capable of carrying out
GDP/GTP exchange for Rac1 in vitro (Fig. 2). Sequence
analysis of Tiam1 suggests that its association with the in-
vasive and metastatic phenotype is mediated via mem-
brane-linked cytoskeletal regulation and/or activation of
Rho family GTPases (Habets et al., 1994; Nobes and Hall,
1995).
Rac1 acts downstream of Tiam1 signaling and regulates
the function of several cell adhesion molecules such as the
laminin receptor, a6b1 integrin (Van Leeuwen et al.,
1997), E-cadherin (Hordijk et al., 1997), and the hyaluro-
nan receptor, CD44 (Bourguignon et al., 2000). Tiam1-
Rac1 activation also has been shown to be stimulated by
certain serum-derived growth activators (e.g., S1P and
LPA) during T-lymphoma cell invasion (Stam et al., 1998).
However, in epithelial MDCK cells, Tiam1-Rac1 signaling
plays an invasion/suppressor role in Ras-transformed
MDCK cells (Hordijk et al., 1997). Apparently, various re-
sponses by Tiam1-catalyzed Rac1 signaling may be con-
trolled by selective upstream activators (e.g., availability
of certain cytoskeletal proteins [e.g., ankyrin], cell adhe-
sion receptors [e.g., CD44, integrin or E-cadherin], growth
activators [e.g., serum, S1P, or LPA] or extracellular ma-
trix components [hyaluronic acid, collagen, or fibronectin,
etc.]). Moreover, Tiam1 is found to be involved in promot-
ing both Rac1- and RhoA-mediated pathways during neu-
rite formation in nerve cells (Van Leeuwen et al., 1997).
The balance between Rac1 and RhoA determines a partic-
ular cellular morphology and migratory behavior (Sander
et al., 1999).
Ankyrin is a family of membrane-associated cytoskeletal
proteins expressed in a variety of biological systems in-
cluding epithelial cells and tissues (Peters and Lux, 1993).
Presently, at least three ankyrin genes have been identi-
fied: ankyrin 1 (Ank 1 or ankyrin R), ankyrin 2 (Ank 2 or
ankyrin B), and ankyrin 3 (Ank 3 or ankyrin G; Lux et al.,
1990; Otto et al., 1991; Kordeli et al., 1995; Peters et al.,
1995). These molecules belong to a family of related genes
that probably arose by duplication and divergence of a
common ancestral gene. Ankyrin is known to bind to a
number of plasma membrane–associated proteins includ-
ing the following: band 3, two other members of the anion
exchange gene family (Bennet, 1992), Na1/K1-ATPase
(Nelson and Veshnock, 1987; Zhang et al., 1998), the
amiloride-sensitive Na1 channel (Smith et al., 1991), the
voltage-dependent Na1 channel (Kordeli et al., 1995),
Ca21 channels (Bourguignon et al., 1993b, 1995a; Bour-
guignon and Jin, 1995) and the adhesion molecule CD44
(Bourguignon et al., 1986, 1991, 1992, 1993a; Kalomiris
and Bourguignon, 1988, 1989; Lokeshwar and Bourguig-
non, 1991, 1992; Lokeshwar et al., 1994, 1996). It has been
suggested that the binding of ankyrin to certain mem-
brane-associated molecules is necessary for signal trans-
duction, cell adhesion, membrane transport, cell growth,
migration, and tumor metastasis (Bennet, 1992; Bourguig-
non et al., 1995b, 1996, 1997, 1998a; De Matteis and Mor-
row, 1998; Zhu and Bourguignon, 1998, 2000).
In this study, we have presented new evidence showing
the interaction between ankyrin and Tiam1. Specifically, we
have demonstrated that Tiam1 and ankyrin (e.g., ANK1
and ANK3) are physically linked to each other as a com-
plex in vivo (Figs. 3 and 10) and in vitro (Figs. 5–7), and
that ankyrin binding to Tiam1 promotes Rac1 activation
(Figs. 8 and 11). Using purified Tiam1 and GST-tagged
ankyrin repeat domain (GST-ARD; Fig. 5) to examine the
interaction between Tiam1 and ankyrin in vitro, we have
found that ARD is directly involved in the binding of
Tiam1 (Fig. 5, C and D, and Fig. 6, C–E). In fact, the bind-
ing affinity of ARD to Tiam1 is very comparable to that of
intact erythrocyte ankyrin binding to Tiam1 (Fig. 5, C and
D). These findings support the conclusion that the ARD
fragment of ankyrin is directly involved in the recognition
of Tiam1. The 24 ankyrin repeats within the ARD are
known to form binding sites for at least seven distinct
membrane protein families (Michaely and Bennett, 1995).
Often, ARD is organized into four folding subdomains:
subdomain 1 (S1), subdomain 2 (S2), subdomain 3 (S3),
and subdomain 4 (S4)). Recently, we have shown that the
S2 subdomain, but not the other subdomains, of ARD
binds to the adhesion molecule CD44 directly (Zhu and
Bourguignon, 2000). Overexpression of subdomain (S2)
of ARD promotes CD44-mediated tumor cell migration
(Zhu and Bourguignon, 2000). The question of which
ARD subdomain fragment(s) is (are) involved in regulat-
ing Tiam1 function remains to be determined.
The structural homology between the ankyrin binding
domain of Tiam1 (the sequence between amino acids 717
and 727) and CD44 is quite striking (Lokeshwar et al.,
1994). The cytoplasmic domain of CD44 (z70 amino acids
long) is highly conserved ($90%) in most of the CD44 iso-
forms; and it is clearly involved in specific ankyrin binding
(Lokeshwar et al., 1994; Zhu and Bourguignon, 1998). The
ankyrin-binding domain of CD44 has also been mapped
using deletion mutation analyses and mammalian expres-
sion systems (Lokeshwar et al., 1994; Zhu and Bour-
guignon, 1998). In particular, the ankyrin-binding domain
(e.g., NGGNGTVEDRKPSEL between amino acids 306
and 320 in the mouse CD44 [Lokeshwar et al., 1994] and
NSGNGAVEDRKPSGL amino acids 304 and 318 in hu-
man CD44 [Zhu and Bourguignon, 1998]) is required for
cell adhesion (Lokeshwar et al., 1994; Zhu and Bour-
guignon, 1998), the recruitment of Src kinase (Zhu and
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Bourguignon, 1998), and the onset of tumor cell transfor-
mation (Bourguignon et al., 1998b; Zhu and Bourguignon,
1998). The facts that (1) the recombinant C1199 Tiam1 in-
teracts with ARD fusion protein directly with a stoichiom-
etry of 1:1 (Fig. 6, D and E); (2) a peptide with the se-
quence 717GEGTDAVKRS727L of Tiam1 binds to ankyrin
and ARD but not ankyrin’s spectrin binding domain or
spectrin (Table I); (3) a Tiam1 peptide (amino acids 717–
727) competes with Tiam1 for the binding to ankyrin (Fig.
7 A); (4) the Tiam1 deletion mutant protein (e.g., C1199
Tiam1D717-727; Fig. 7 B) fails to bind ankyrin (Fig. 7 D);
and (5) ankyrin stimulates Tiam1-catalyzed GDP/GTP ex-
change activity on Rac1 (Fig. 8) strongly suggest that the
sequence (717GEGTDAVKRS727L) of Tiam1 is an im-
portant region for ankyrin binding.
Furthermore, we have shown that transfection of SP-1
cells with HA-tagged NH2 terminally truncated C1199
Tiam1 cDNA stimulates ankyrin-associated GDP/GTP ex-
change on Rac1 (Fig. 11) as well as tumor cell invasion (Ta-
ble II, A) and migration (Table II, B). These Tiam1-acti-
vated oncogenic responses are consistent with previous
studies indicating that Tiam1-activated Rho-like GTPases
may act as downstream effectors of Ras in both tumori-
genesis and progression to metastatic diseases (Habets et
al., 1994, 1995; van Leeuwen et al., 1995). The amino acids
393–738 Tiam1 fragment (Fig. 6 C) contains not only the
putative ankyrin-binding domain (amino acids 717–727),
but also the NH2-terminal pleckstrin homology (PHn), the
coiled-coil region (CC) and an additional adjacent region
(Ex) (also designated as PHn-CC-Ex domain; Michiels et
al., 1997). This Tiam1 fragment has been shown to be re-
sponsible for Tiam1’s membrane localization, Rac1-depen-
dent membrane ruffling, and C-Jun NH2-terminal kinase
activation in fibroblasts and COS cells (Michiels et al.,
1997; Stam et al., 1997). In this study, we have found that
cotransfection of SP1 cells with Tiam1 fragment cDNA
and C1199 Tiam1 cDNA effectively blocks tumor cell–
specific behaviors (e.g., C1199 Tiam1 association with
ankyrin in the cell membrane [Fig. 10], Rac1 activation
[Fig. 11], tumor cell invasion [Table II, A], and migration
[Table II B]). These findings further support our conclu-
sion that the ankyrin-binding domain-containing Tiam1
fragment acts as a potent competitive inhibitor, which is
capable of interfering with C1199 Tiam1–ankyrin interac-
tion in vivo. Recently, we have also demonstrated that the
Tiam1 fragment is required for CD44 (the hyaluronan re-
ceptor) binding (Bourguignon et al., 2000). Most impor-
tantly, Tiam1–CD44 interaction promotes Rac1 activation
and hyaluronic acid–mediated breast tumor cell migration
(Bourguignon et al., 2000). These observations clearly sug-
gest that the amino acids 393–738 of Tiam1 contains multi-
ple functional domains (e.g., membrane localization site(s)
and cytoskeleton binding domains) required for the regu-
lation of Tiam1-Rac1 signaling and cytoskeleton function.
Taken together, we believe that ankyrin–Tiam1 interac-
tion plays a pivotal role in regulating Rac1-activated on-
cogenic signaling and cytoskeleton-mediated metastatic
breast tumor cell progression.
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